Company Performance Metrics
Hye-Shin Chung: CTO and Co-Founder- Soon Jae Park: CEO
Founded in 2008, Alteogen is a leading bio company whose portfolio includes next-generation Biobetter, with improved efficacy in comparison with existing biologics, biosimilars that demonstrate “comparability” to the existing biologics, and proprietary biologics. Alteogen focus on the three cutting edge areas of the industry – long-acting
biobetters, proprietary antibody-drug conjugate, and antibody biosimilars with complexity. Currently, Alteogen has developed NexP™ Fusion Technology, a next-generation long-acting biobetter technology on its own, developed NexMab™ ADC Technology, an Antibody-Drug Conjugate technology, novel human hyaluronidase PH 20 based on Hybrozyme Technology and is jointly developing Antibody Biosimilars with overseas strategic alliance partners.
